NEU² Partners: Biotest
Biotest AG, headquartered in Dreieich, Germany, is a specialist in immunology and hematology with around 2,000 employees worldwide. Biotest is offering a range of products and services for treating diseases of the immune system and the blood that cover the entire value chain from development to market. With its core business, plasma proteins, Biotest is the world market leader for a number of indications such as preparations for hepatitis B reinfection after liver transplantation. In the area of biotherapeutics the company is developing three monoclonal antibodies for different indications. BT-061, the leading candidate, is in clinical development for the treatment of Rheumatoid Arthritis and Psoriasis, and showed promising preclinical data indicating potential also for treatment of multiple sclerosis. Biotest is going to evaluate this potential in the context of the NEU² consortium.